Life Sciences Tools and Services
Company Overview of SeraCare Life Sciences, Inc.
SeraCare Life Sciences, Inc. provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company’s Diagnostic and Biopharmaceutical Products segment offers controls and panels for the evaluation and quality control of infectious disease tests in clinical laboratories, blood banks, and in vitro diagnostic (IVD) manufacturing; and reagents and bioprocessing products for use in the discovery, development and manufacturing processes for drugs, vaccines, and diagnostic tests. It also provides diagnostic intermediates for use in manufacturing diagnostic test kits; cell culture additives and media that maintain viabi...
37 Birch Street
Milford, MA 01757
Founded in 1984
Key Executives for SeraCare Life Sciences, Inc.
Chief Executive Officer and President
Chief Financial Officer and Secretary
Vice President of Human Resources
Vice President of Manufacturing Operations
Compensation as of Fiscal Year 2014.
SeraCare Life Sciences, Inc. Key Developments
SeraCare Life Sciences Introduces New Accuspan Molecular Linearity Panels
Nov 4 14
SeraCare Life Sciences announced seven new AccuSpan(TM) molecular linearity panels for the detection of Adenovirus (ADV), Varicella Zoster Virus (VZV), JC Virus (JCV), Herpes Simplex Virus 1 (HSV1), Herpes Simplex Virus 2 (HSV2), Epstein Barr Virus (EBV), and BK Virus (BKV). These new linearity panels from SeraCare help assay developers thoroughly challenge their transplant assays from extraction phase through amplification. Each panel consists of four members: one negative, one low positive, one medium positive, and one high positive sample. These panels are provided in a ready-to-go single-use format with target concentrations that cover the dynamic range of most molecular assays and are consistent within each lot and across batches.
SeraCare Life Sciences Introduces New ACCURUN(R) C. difficile Control Set
Aug 22 14
SeraCare Life Sciences, Inc. announced the launch of its new ACCURUN(R) 501 C. difficile Control -- the company's first molecular control product targeting hospital acquired infections. ACCURUN 501 C. difficile Control is formulated for use with in vitro diagnostic tests that detect C. difficile DNA in human stool samples. Manufactured from cultured Clostridium bacteria of four different strains or species delivered in a set of four vials, the bacteria are inactivated and in a human synthetic stool matrix. The control is ready-to-use in assays that detect C. difficile DNA with any transport system.
SeraCare Life Sciences Expands Genetic Portfolio with New Accurun(R) Product
Apr 8 14
SeraCare Life Sciences announced the launch of its new ACCURUN(R) 611 product, a robust product that demonstrates consistent performance over time. This reference material is designed to support detection of the Factor V Leiden mutation and the Factor II gene variant, as well as mutations in the Methlyenetetrahydrofolate reductase (MTHFR) gene that are associated with significant health problems. ACCURUN(R) 611 meets the needs of a broad range of molecular lab applications by providing heterozygous, mutant, or wild type scores for Factor II, Factor V, and MTHFR. It is ready-to-use genomic DNA manufactured from immortalized Peripheral Blood Mononuclear Cells (PBMCs) derived from human samples. Mutations were confirmed by a variety of commercial SNP genotyping assays, providing a robust challenge for all mutations in only two vials.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|